Ischaemia-reperfusion injury in the isolated haemoperfused bovine uterus: an in vitro model of acute inflammation.
Following on from previous studies on dermal inflammation in the isolated perfused bovine udder, a new in vitro model of the isolated haemoperfused bovine uterus was established for studies on acute inflammatory reactions (for example, eicosanoid synthesis and regulation of cyclooxygenase-1 [COX-1] and COX-2) caused by ischaemia-reperfusion (I-R) injury. The organs and blood used in this study were obtained from a slaughterhouse. Within 2 hours of slaughter, uterine perfusion was re-established, by using a mixture of homologous blood and Tyrode solution (4:1). After equilibration, several deposits of arachidonic acid (5 mg and 0.1 mg) and arachidonylethanolamide (0.1 mg) were injected into the myometrial tissue. Tissue biopsies were taken from treated and untreated areas at 180 and 300 minutes after the onset of haemoperfusion, for measuring prostaglandin E(2) (PGE(2)) levels. In addition, the regulation of COX-1 and COX-2 mRNA was investigated by using the reverse transcriptase-polymerase chain reaction. Eicosanoid levels were determined by using an enzyme immunoassay (ELISA). Because both an increase in PGE(2) concentration and up-regulation of COX mRNA were observed, the inhibitory effects of dexamethasone, added to the perfusion medium, were studied. Dexamethasone caused a significant decrease in tissue PGE(2) production, but did not induce down-regulation of COX-2 mRNA. In conclusion, the isolated haemoperfused bovine uterus was introduced as an in vitro model of acute inflammation, induced by I-R injury. The suitability of the model for investigating anti-inflammatory substances was demonstrated. Use of the isolated haemoperfused bovine uterus in pharmacological research and drug screening may contribute to reducing the number of animals used for testing.
Braun
Michael
M
Department of Pharmacology, Toxicology and Pharmacy, School of Veterinary Medicine, Buenteweg 17, 30559 Hannover, Germany. michael.braun@tiho-hannover.de
Kietzmann
Manfred
M
D000826:Animal Testing Alternatives; D000818:Animals; D016718:Arachidonic Acid / Q000008:administration & dosage / Q000494:pharmacology; D001095:Arachidonic Acids / Q000494:pharmacology; D002417:Cattle; D051546:Cyclooxygenase 2; D003907:Dexamethasone / Q000494:pharmacology; D015232:Dinoprostone / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D063388:Endocannabinoids; D005260:Female; D005786:Gene Expression Regulation / Q000187:drug effects; D006464:Hemoperfusion; D007249:Inflammation / Q000503:physiopathology*; D007527:Isoenzymes / Q000378:metabolism*; D009215:Myometrium / Q000378:metabolism; D009924:Organ Culture Techniques / Q000662:veterinary*; D053284:Polyunsaturated Alkamides; D011451:Prostaglandin-Endoperoxide Synthases / Q000378:metabolism*; D015427:Reperfusion Injury / Q000503:physiopathology*; D015854:Up-Regulation; D014599:Uterus / Q000098:blood supply / Q000187:drug effects / Q000503:physiopathology*
D001095:Arachidonic Acids; D063388:Endocannabinoids; D007527:Isoenzymes; D053284:Polyunsaturated Alkamides; D016718:Arachidonic Acid; D003907:Dexamethasone; D051546:Cyclooxygenase 2; D011451:Prostaglandin-Endoperoxide Synthases; D015232:Dinoprostone; C078814:anandamide